The role of liver X receptor (LXR) in pancreatic b-cell physiology and pathophysiology is still unclear. It has been postulated that chronic LXR activation in b-cells induces lipotoxicity, a key step in the development of b-cell dysfunction, which accompanies type 2 diabetes mellitus. In most of these studies, the LXR ligand T0901317 has been administered chronically in the micromolar range to study the significance of LXR activation. In the current study, we have evaluated acute effects of T0901317 on stimulus-secretion coupling of b-cells. We found that 10 mM T0901317 completely suppressed oscillations of the cytosolic Ca 2+ concentration induced by 15 mM glucose. Obviously, this effect was due to inhibition of mitochondrial metabolism. T0901317 markedly depolarized the mitochondrial membrane potential, thus inhibiting adenosine triphosphate (ATP) production and reducing the cytosolic ATP concentration. This led in turn to a huge increase in K ATP current and hyperpolarization of the cell membrane potential. Eventually, T0901317 inhibited glucose-induced insulin secretion. These effects were rapid in on-set and not compatible with the activation of a nuclear receptor. In vivo, T0901317 acutely increased the blood glucose concentration after intraperitoneal application. In summary, these data clearly demonstrate that T0901317 exerts acute effects on stimulus-secretion coupling. This observation questions the chronic use of T0901317 and limits the interpretation of results obtained under these experimental conditions. (Endocrinology 158: [2145][2146][2147][2148][2149][2150][2151][2152][2153][2154] 2017) T he liver X receptor (LXR) is a member of the family of transcription factors and is closely related to nuclear receptors, such as the peroxisome proliferator-activated receptors, the farnesoid X receptor (FXR), and the retinoid X receptor. These receptors are important regulators of lipid and glucose homeostasis (1-3). Interestingly, in liver LXR acts as a glucose sensor (i.e., physiological glucose concentrations induce expression of LXR target genes with an efficacy similar to that of oxysterols, the known endogenous LXR ligands) (4). During the last years, it became evident that these receptors not only affect insulin sensitivity and glucose handling in peripheral organs like liver, but also affect b-cell function. LXRa and LXRb are present in pancreatic islets and insulin-secreting MIN6 cells (5). As LXR belongs to a group of nuclear receptors, it is commonly expected that stimulation of LXR induces changes in gene expression. However, the consequences of LXR activation for b-cell function are still a matter of debate. This may be owing to the fact that in most studies chronic administration of the LXR ligand T0901317 in the micromolar range was chosen to activate the LXR. Efanov et al. (5) showed that 1 mM T0901317 enhanced glucoseinduced insulin secretion of rat islets. However, an important effect of the compound was first seen at day 3 of
effect was due to inhibition of mitochondrial metabolism. T0901317 markedly depolarized the mitochondrial membrane potential, thus inhibiting adenosine triphosphate (ATP) production and reducing the cytosolic ATP concentration. This led in turn to a huge increase in K ATP current and hyperpolarization of the cell membrane potential. Eventually, T0901317 inhibited glucose-induced insulin secretion. These effects were rapid in on-set and not compatible with the activation of a nuclear receptor. In vivo, T0901317 acutely increased the blood glucose concentration after intraperitoneal application. In summary, these data clearly demonstrate that T0901317 exerts acute effects on stimulus-secretion coupling. This observation questions the chronic use of T0901317 and limits the interpretation of results obtained under these experimental conditions. (Endocrinology 158: [2145] [2146] [2147] [2148] [2149] [2150] [2151] [2152] [2153] [2154] 2017) T he liver X receptor (LXR) is a member of the family of transcription factors and is closely related to nuclear receptors, such as the peroxisome proliferator-activated receptors, the farnesoid X receptor (FXR), and the retinoid X receptor. These receptors are important regulators of lipid and glucose homeostasis (1) (2) (3) . Interestingly, in liver LXR acts as a glucose sensor (i.e., physiological glucose concentrations induce expression of LXR target genes with an efficacy similar to that of oxysterols, the known endogenous LXR ligands) (4) . During the last years, it became evident that these receptors not only affect insulin sensitivity and glucose handling in peripheral organs like liver, but also affect b-cell function. LXRa and LXRb are present in pancreatic islets and insulin-secreting MIN6 cells (5) . As LXR belongs to a group of nuclear receptors, it is commonly expected that stimulation of LXR induces changes in gene expression. However, the consequences of LXR activation for b-cell function are still a matter of debate. This may be owing to the fact that in most studies chronic administration of the LXR ligand T0901317 in the micromolar range was chosen to activate the LXR. Efanov et al. (5) showed that 1 mM T0901317 enhanced glucoseinduced insulin secretion of rat islets. However, an important effect of the compound was first seen at day 3 of administration. The stimulatory effect on insulin secretion was completely blocked by the pyruvate carboxylase inhibitor phenylacetic acid.
In MIN6 cells inhibition of glucose-induced insulin secretion was observed after 48 hours treatment with 2, 5, and 10 mM T0901317, respectively (6) . Under these conditions, the authors found a small reduction in adenosine triphosphate (ATP) content of MIN6 cells and an increase in K ATP current. Inhibitory effects on glucoseinduced insulin secretion by chronic T0901317 administration were also reported for HIT cells and mouse islets (7) . Accordingly, the authors report that glucose tolerance is deteriorated in mice treated with T0901317 for 1 week. This contrasts with the finding that LXRbknockout (KO) mice show impaired glucose tolerance (8) . Islets from these mice have reduced glucose-induced insulin secretion. Noteworthy, LXRa-KO mice and mice that lack both receptor subtypes are not glucoseintolerant. Another study reveals that chronic activation of LXR by 10 mM T0901317 in b-cells and INS-1 cells induces reactive oxygen species (ROS) and lipid accumulation leading to lipotoxicity and apoptosis (9). Liang et al. (10) showed that 10 mM T0901317 enhanced palmitate-induced apoptosis in INS-1 cells. LXR is also present in human islets (11) . In this study, it was shown that preincubation with 1 mM T0901317 increased glucose-induced insulin secretion of isolated human islets. The importance of LXR for human islets is also demonstrated by the fact that in subjects of European ancestry at increased risk for type 2 diabetes, a common variation within the NR1H2 gene (encoding LXRb) impaired insulin secretion, which may facilitate the development of type 2 diabetes (12). Taken together, the studies indicate a physiological significance of LXR in b-cells although a proof is missing that the effects observed with T0901317 are mediated by LXR activation.
In this study, we tested T0901317 for acute alterations in b-cell function. According to our data it cannot be excluded that changes in gene expression in response to T0901317 treatment (6, 9, 10) are due to rapid ATP depletion (13, 14) and not primarily and/or exclusively caused by LXR activation.
Materials and Methods

Cell and islet preparation
The details are described in Gier et al. (15) . Male and female C57Bl/6 mice were used in equal shares. The FXR-KO mice on a C57Bl/6 background were housed under same conditions. The mice were bred in the animal facility of the Department of Pharmacology at the University of Tübingen. The principles of laboratory animal care (NIH publication no. 85-23, revised 1985; 16) and German laws were followed. Mouse islets were dispersed to single cells and cell clusters, respectively, by trypsin treatment.
Human islets were obtained from two biopsies from children aged 6 and 11 months with focal congenital hyperinsulinism during pancreatic surgery according to the approvals of the ethic commission of the Universitätsmedizin Greifswald (BB 050/13). The children are carriers of mutations in the ABCC8 gene, which encodes for the SUR1 subunit of the K ATP channel. The islets were taken from areas not affected by the mutations. They were isolated by injecting collagenase (2 to 4 mg/mL) into the biopsy material and by handpicking after digestion at 37°C. Human islets were cultured in a medium with 5.5 mM glucose. T0901317 and GW3965 were obtained from Biomol (Hamburg, Germany). Fura-2-AM was purchased from Biotrend (Köln, Germany) and 25-OH cholesterol from Santa Cruz (Heidelberg, Germany). Rhodamine 123 (Rh123), CMRL medium, RPMI 1640 medium, fetal calf serum, 2',7'-dichlorodihydrofluorescein-diacetate (DCDHF-DA), dihydroethidium (DHE), ATP determination kit, and penicillin/ streptomycin were from Invitrogen (Karlsruhe, Germany). Collagenase used for human biopsy material was obtained from Serva (Heidelberg, Germany). All other chemicals were purchased from Sigma (Deisenhofen, Germany) or Merck (Darmstadt, Germany) in the purest form available.
Solutions and chemicals
Measurement of [Ca 2+ ] c
Details are described in Gier et al. (15) . In brief, cells were loaded with 5 mM Fura-2-AM for 35 minutes at 37°C. Fluorescence was excited at 340 and 380 nm, and emission was filtered (LP515) and measured by a digital camera. [ 
Measurements of DC
DC was measured as Rh123 fluorescence at 480-nm excitation wavelength as described in Edalat et al. (17) . To evaluate the effects, the values were averaged over 50 seconds at the end of each interval.
ATP measurement
After preparation, 20 islets were incubated for 30 minutes at 37°C in incubation medium containing either 15 mM glucose or 15 mM glucose and 30 mM T0901317. The incubation medium was removed, and islets were lysed in a solution containing 200 mM NaOH and 0.5 mM EDTA. Enzymes were inhibited by heat (60°C). The ATP concentration of the samples was determined on the same day luminometrically with a Luminometer 1253 (Bioorbit, Turku, Finland). Bioluminescence assays were performed in triplicate by adding 10 mL of test solution to 490 mL standard reaction solution, which was prepared according to the instructions of the manufacturer.
Patch-clamp measurements
Patch pipettes were pulled from borosilicate glass capillaries (Harvard Apparatus, March-Hugstetten, Germany). Membrane currents and potentials were recorded with an EPC-9 patch-clamp amplifier using "Patchmaster" software (HEKA, Lambrecht, Germany). As with T0901317, too many channels were open to resolve single channel open probability, so K ATP channel activity was determined by averaging the current over baseline for the last 30 seconds. For V m measurements, the plateau potential in the control and wash-out phases as well as the most negative potential during the administration of T0901317 was measured. For inside-out measurements, K ATP currents were determined at a membrane potential of 250 mV. Single channel open probability was analyzed for the last 15 seconds.
Measurements of electrical activity by the MEA technique
Extracellular potential recordings were obtained with the MEA technique as described previously (18) using a MEA 2100 amplifier system and MC-Rack software (Multi Channel System, Reutlingen, Germany). An islet was placed on an electrode by means of a glass holding pipette (Reproline, Rheinbach, Germany) and a micromanipulator (Scientifica, Uckfield, UK). For analysis, the fraction of plateau phase (FOPP~percentage of time with burst activity) was calculated by Jupyter Notebook using an IPython in house-made protocol, which analyzes the typical pattern of the extracellular potential. The FOPP was determined over 15 minutes at the end of each experimental maneuver.
Insulin secretion
Details for steady-state incubations are described in Gier et al. (15) . Briefly, after preparation, islets were kept overnight in RPMI 1640 culture medium with 11.1 mM glucose. Before starting secretion experiments, islets were kept for 1 hour in KRH solution with 5.6 mM glucose and for further 30 minutes in a KRH solution with 3 mM glucose to silence metabolic activity. After this procedure, insulin in the supernatant was collected for 1 hour at 37°C under conditions as indicated. Levels of insulin were determined by radioimmunoassay (Merck Millipore, Darmstadt, Germany).
In vivo application of T0901317
For in vivo experiments, male C57Bl/6 mice at an age of 5 months were used. T0901317 dissolved in dimethyl sulfoxide was injected intraperitoneally (IP) at a concentration of 50 mg/kg body weight. Control mice received dimethyl sulfoxide. Blood glucose concentration (BGC) was determined directly before the injection and 5, 10, 20, 40, and 60 minutes thereafter. During the experiment, mice had free access to water and food.
Measurement of ROS
ROS production was measured by using the fluorescent dyes DCDHF-DA and DHE. In the cells, DCDHF-DA is oxidized to the fluorescent 2',7'-dichlorofluorescein (DCF), which detects H 2 O 2 and other ROS species. DHE is oxidized to 2-hydroxyethidium (2-OH-E + ), which mainly indicates O 2 2 formation. After 1-hour incubation under conditions as indicated, the clusters were loaded for 15 minutes with 20 mM DCDHF-DA and 10 mM DHE, respectively. Fluorescence was excited at 480 nm, and the intensity of the emitted light [arbitrary units (a.u.)] was measured.
Statistics
Each series of experiments was performed with islets or islet cells from at least three independent preparations. Means 6 standard error of the mean are given for the indicated number of experiments (cells or islets). Statistical significance of differences was assessed by using Student t test. Multiple comparisons were made by analysis of variance followed by Student-NewmanKeuls test. P values # 0.05 were considered significant.
Results
Effects of T0901317 on the cytosolic Ca ] c dropped to 53 6 14 nM (asterisk). During the continued wash-out phase, it augmented to 427 6 64 nM (arrowhead). Because FXR (NR1H4) and LXR (a NR1H3 and b NR1H2) belong to a group of nuclear receptors with structural similarities and act on metabolism in a coordinated manner (19), we wanted to exclude that T0901317 affects the FXR. T0901317 had identical effects in b-cells of FXR-KO mice (Supplemental Fig. 1) . Thus, the drug seems not to affect the FXR. Preincubation of wild-type islet cells with 1 mM of the sarco/endoplasmic reticulum Ca 2+ -ATPase inhibitor thapsigargin suppressed the drop in [Ca 2+ ] c at the beginning of the wash-out phase [ Fig. 1(c) and 1(d) , asterisk] showing that the drop in [Ca 2+ ] c seen in Fig. 1 (a) (asterisk) was due to ATP-dependent Ca 2+ sequestration into the endoplasmic reticulum (20) . As mentioned earlier, LXR was found in human islets (11 ] c (Supplemental Fig. 2 ).
Effect of T0901317 on the DC of b-cells and ATP concentration of islets
The DC is directly linked to ATP production (21) . As shown in Fig. 2(a) a rise in the glucose concentration that causes an immediate increase in ATP production is accompanied by a hyperpolarization of DC indicated by a decrease of the fluorescence signal. The fluorescence signal was lowered from 1501 6 71 a.u. in the presence of 0.5 mM glucose to 1283 6 59 a.u. upon an increase of the glucose concentration to 15 mM. A concentration of 10 mM T0901317 strongly and reversibly depolarized DC to 1511 6 75 a.u. After wash-out of the compound DC repolarized again to 1282 6 60 a.u. [ Fig. 2(b) ]. Accordingly, the ATP concentration of islets decreased from 3.3 6 0.1 pmol/islet in the presence of 15 mM glucose to 2.0 6 0.2 pmol/islet after addition of 30 mM T0901317 [ Fig. 2(c) ]. In contrast to the measurements with dispersed islet cells or clusters of cells, these measurements with whole islets, which are encircled by a capsule of connective tissue, were performed with 30 mM T0901317. This capsule may reduce the diffusion of T0901317 (see also MEA measurements and insulin secretion). 
Influence of T0901317 on K ATP current and electrical activity
As T0901317 influences DC and thus ATP concentration, it should also affect the K ATP current and the membrane potential of b-cells. Figure 3(a) shows an experiment recorded in the cell-attached configuration. An increase of the glucose concentration from 0.5 to 15 mM was accompanied by a complete block of K ATP channels and action potentials were elicited as indicated by small capacitive artifacts (arrow). The K ATP current was reduced from 1.56 6 0.25 pA to 0 6 0.02 pA. Treatment of the cells with T0901317 led to an enormous rise in the K ATP current to 12.81 6 3.35 pA. Addition of the sulfonylurea tolbutamide almost completely inhibited the current (0.41 6 0.28 pA) identifying it as current through K ATP channels [summarized in Fig. 3(b) ]. In excised patches (inside/out configuration), ATP dramatically reduced K ATP channel activity to almost zero [ Fig. 3(c) and summary in Fig. 3(d) ]. T0901317 was unable to reopen the channels under this condition showing that the effect of T0901317 is dependent on intact cell metabolism. According to the observations on K ATP current in the cell-attached configuration, T0901317 markedly hyperpolarized V m from the plateau potential (potential from which action potentials start) in 10 mM glucose of 226 6 2 mV to 257 6 5 mV [ Fig. 3(e) and 3(f) ]. After wash-out of the drug the plateau, potential amounted to 224 6 2 mV. Similar results were obtained when electrical activity was measured with whole islets on an MEA (Fig. 4) . The FOPP was diminished from 64% 6 9% in the presence of 10 mM glucose to 24% 6 6% after addition of 10 mM T0901317 [ Fig. 4(a) and (b) ]. In 0.5 mM glucose that was used to prove the metabolic integrity of the islets, no electrical activity appeared. A higher concentration of 30 mM T0901317 was necessary to almost completely suppress electrical activity [ Fig. 4 (c) and (d)] because MEA measurements were conducted with whole islets.
Effect of T0901317 on insulin secretion and BGC
Insulin secretion markedly raised upon an increase of the glucose concentration from substimulatory to stimulatory concentration [0.14 6 0.03 ng insulin/(islet * h) in 3 mM glucose versus 5.87 6 0.80 ng insulin/(islet * h) in 15 mM glucose]. Application of 10 and 30 mM T0901317 reduced insulin secretion to 3.73 6 0.71 ng insulin/(islet * h) and 1.43 6 0.29 ng insulin/(islet * h), respectively [ Fig. 5(a) ]. As in the MEA experiments, in secretion studies whole islets were used. Accordingly, 10 mM T0901317 were not as effective as in the experiments performed with dispersed b-cells. To evaluate whether the in vitro observations of acute effects of T0901317 are valid for the situation in vivo, BGC was determined. T0901317 increased BGC after IP injection [ Fig. 5(b) ]. A tendency of a rise in BGC was already 
Discussion
T0901317 has been used in a variety of in vivo and in vitro studies to evaluate its effects on glucose and lipid homeostasis in peripheral tissues and pancreatic b-cells. The results are at least in part contradictory, which may be due to different concentrations of T0901317, the use of different cell systems (primary human and murine b-cells, different insulin-secreting tumor cell lines), and animal models (wild-type mice, diabetes-prone mouse models, high fat diet-induced diabetes, and streptozotocin-induced diabetes). Consistently, the effects have been attributed to LXR activation. Likewise, T0901317 was administered chronically in all studies because there was a consensus that LXR activation by T0901317 resulted in transcriptional effects, which need hours to days to become evident. However, proof is still lacking that all effects observed in response to T0901317 administration are due to changes in gene expression. We have now demonstrated that T0901317 induces rapid changes in various parameters of stimulus-secretion coupling (SSC) in mouse and human b-cells. These changes in SSC are not consistent with genomic effects mediated by transcription factors because they occur within minutes. Moreover, the good and rapid reversibility of the effects speaks against transcriptional pathways. In addition, the in vivo data, which show a substantial rise in the BGC already 20 minutes after IP injection of T0901317, support the idea of a nongenomic effect of T0901317 on insulin secretion in b-cells. Both, LXR and FXR are encoded by the NR1H gene subfamily of nuclear receptors and thus exhibit high homology resulting in numerous commonalities on the protein level. A recent paper describes these coordinated actions of both receptors in metabolism (19) . In principle, activation of a nuclear receptor can induce rapid nongenomic changes in SSC of b-cells. Recently, we have shown this for the FXR (2). Activation of FXR by bile acids or the synthetic ligand GW4064 leads to enhanced insulin secretion via a rapid effect on K ATP channels and subsequent increase of [Ca 2+ ] c . FXR does not directly affect K ATP channels but by a still unknown cellular factor. In the case of FXR, we could prove that the rapid effects on SSC were mediated by FXR activation because they were blunted in islets of FXR-KO mice. FXR activation results in opposite effects in lean and obese mice. In lean mice, glucose tolerance was impaired by FXR deletion, which fits to our observations with isolated islets (22) (23) (24) (25) . Surprisingly, glucose tolerance was improved in obese mice (22, 26) . Based on the observation of other groups and our own, we hypothesized that this difference between lean and obese mice is caused by an obesitymediated translocation of the b-cell FXR from the cytosol to the nucleus (22, 27) . Noteworthy, a translocation between the cellular compartments is also described for the LXR. Glucose regulates the subcellular distribution of the LXRa in insulin-secreting INS-1 cells (28) . At low glucose, LXRa is localized in the cytosol and it is translocated into the nucleus at stimulatory glucose concentration. However, the significance of this observation for b-cell function remains unclear.
Overall, acute administration of the LXR ligand T0901317 to b-cells leads to rapid changes in SSC resulting in inhibition of insulin secretion. These effects are nongenomic, but nevertheless the LXR is presumably involved because two other LXR ligands cause similar acute effects on [Ca 2+ ] c as T0901317. The rapid reversibility of the T0901317 action and the fact that two other LXR agonists evoke similar effects on [Ca 2+ ] c speak against an unspecific toxic effect of the drug on b-cells. Importantly, 10 mM T0901317 that we used for acute application was taken in many studies dealing with consequences of chronic LXR activation on glucose and lipid metabolism (6, 9, 10) . It has been postulated that T0901317 also activates the FXR (29) and acts as a reverse agonist at a novel retinoic acid receptor-related orphan receptor-a/g (RORa and RORg) (30) . According to our observations, FXR activation by T0901317 seems unlikely. Moreover, it would increase and not decrease insulin secretion.
Our data strongly suggest that a primary mode of action of T0901317 is interference with the mitochondrial metabolism: (1) T0901317 strongly and reversibly depolarized DC. These data exclude a direct effect of the drug on K ATP channels but rather point to an indirect metabolismmediated effect. In conclusion, the T0901317-induced depolarization of DC leads to opening of K ATP channels due to ATP depletion, which in turn reduces Ca 2+ influx and insulin secretion (21) . One should also consider in this context that ATP depletion itself can induce changes in gene expression (e.g., via AMPK activation) (13, 14) . Changes in gene expression after T0901317 treatment are described in a variety of papers (6, 9, 10, 31-34) and have always been taken as an argument for genomic effects of LXR activation. Besides its effect on ATP production, T0901317 interferes with ROS formation, which may also be attributed to the T0901317-induced disturbance of mitochondrial metabolism because Ca 2+ homeostasis, ATP production, ROS formation, and mitochondria are tightly connected (35) . Thus, ROS imbalance may affect mitochondria and finally DC. T0901317 completely suppressed the glucose-evoked increase in DCF fluorescence. ROS production (36) especially H 2 O 2 (37) seems to be an important signal for glucose-induced insulin secretion. Lack of this effect may contribute to the inhibitory action of T0901317 on insulin secretion. It is extremely important to understand the action of T0901317 because fundamental although contradictory conclusions have been drawn from studies with chronic application of this drug: (1) On the one hand, it has been reported that T0901317 leads to improvement of insulin sensitivity (38) (39) (40) , protection against high fat dietinduced (41) as well as streptozotocin-induced (42) diabetes and increased insulin secretion (11) . These studies recommend the development of LXR agonists for clinical use. (2) On the other hand, it has been demonstrated that T0901317 results in b-cell dysfunction via lipid accumulation (6, 9, 43) . For valid interpretation of the results, future studies should take into account that T0901317 can exert acute effects of nongenomic nature. Moreover, LXR-KO mice are available (44) and should be used in the future, if possible, to discriminate between LXRdependent and -independent effects of T0901317.
